Prescient Therapeutics reported a stable financial quarter ending March 2024 with $15.8 million in cash reserves, aligning with budget expectations, and significant progress in the clinical development of PTX-100 for T-cell lymphomas, including favorable Phase 1b study results presented at a specialist conference.
The company also decided to discontinue the development of PTX-200 due to shifting market conditions and cost considerations, while continuing to advance its innovative cancer therapy platforms, CellPryme and OmniCAR, in pre-clinical stages.
ASX Code : PTX